One of the most common forms of malignant brain tumor is called glioblastoma multiforme, which is usually fatal within 6 to 14 months. In fact, only 15 to 26 percent of sufferers will live two years — making it, also, one of the most deadly cancers.
Over the past 40 years, we have seen no real improvements in survival with this tumor, despite the use of extensive chemotherapy and radiation treatments.
Thankfully, a recent report in the “New England Journal of Medicine” may have defined a new treatment that holds promise against this very resistant tumor.
For some time, it has been known that a common virus, called the cytomegalovirus, is closely associated with the glioblastoma multiforme tumor. The researchers found that patients with low levels of this virus lived considerably longer (33 months) than patients with high levels of the virus (13 months).
Based on this finding, people with glioblastoma tumors were given either a drug that kills the virus or conventional treatments (for the control patients).
Patients who received the antiviral drug lived much longer. The two-year survival in those on the drug for six months was 70 percent, with an overall survival of 30.1 months.
On the other hand, patients getting the antiviral drug continuously had a two-year survival of 90 percent, and overall survival of 54.4 months.
The bad news is that the antiviral drug used has a cost of $50,000 a year.
Macrophage-boosting factors called GcMAF can dramatically boost the antiviral capability of the immune system. This factor is available and costs far less than the antiviral drug.
It has also been shown that glioblastoma patients on high dose vitamin D3 live much longer and GcMAF is a carrier for vitamin D3. The more vitamin D3 a person takes, the more GcMAF is produced. Beta-1,3/1,6 glucan also inhibits this virus.
A number of flavonoids have also shown antiviral effects, including curcumin and resveratrol.
© 2021 NewsmaxHealth. All rights reserved.